Yüklüyor......
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
We reviewed preclinical data and clinical development of MDM2 (murine double minute 2), ALK (anaplastic lymphoma kinase) and PARP (poly [ADP-ribose] polymerase) inhibitors. MDM2 binds to p53, and promotes degradation of p53 through ubiquitin-proteasome degradation. JNJ-26854165 and RO5045337 are 2 s...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3103487/ https://ncbi.nlm.nih.gov/pubmed/21504625 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-4-16 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|